Background/Objective: The fragile X-associated tremor/ataxia syndrome is characterized by intention tremor and ataxia in people who are premutation carriers of the Fragile X gene. Patients with this disorder might also demonstrate signs of dementia with parkinsonian features. We report a patient with dementia and parkinsonian signs who did not demonstrate an intention tremor or gait ataxia.
T he fragile X syndrome is caused by a mutation in the FMR1 gene on the Xq27.3 chromosome, where there are excessive repeats (>200) of the CGG sequence. 1 Many children with this disorder have big ears and long faces with impaired verbal communication and social interactions. They often perform repetitive-stereotypic behaviors and are classified as having autism-spectrum disorders. 2 Studies of women who are ''premutation carriers'' with 55 to 200 CGG repeats after they reach the age of 50 years may develop a tremor with ataxia, a neuropathy, along with some parkinsonian features and dementia, ''fragile X-associated tremor/ataxia syndrome (FXTAS).'' 3, 4 Imaging studies of patients with FXTAS show atrophy of the cerebellum, brain stem, and cerebrum as well as evidence of white matter disease that is in the middle cerebellar peduncle, subcortical, and periventricular regions. 5 We report the clinical and pathologic findings of a woman, who had 2 sons with fragile X syndrome and developed dementia with parkinsonian features (PD), but no ataxia, intention tremor, or neuropathy typical of FXTAS. The findings described herein expand the spectrum of fragile X-associated neurologic disease.
METHODS

Case Report Brief History
This 58-year-old right-handed woman was evaluated for a rapidly progressive dementia, characterized by getting lost, poor judgment, and hygiene. These symptoms started 1 to 2 years before being seen by us. She subsequently developed visual hallucinations and paranoid delusions and then lost the ability to converse. She then also developed signs of parkinsonism including a resting tremor and bradykinesia (including walking slowly and slight instability), but no action or intention tremor. Her dementia continued to progress until she was unable to care for herself.
She had a past history of depression, with 2 suicide attempts, but otherwise had a normal life with 2 years of college and worked as a secretary. She was married and had 2 sons with fragile X retardation syndrome and 1 normal daughter. When tested she was found to be a ''carrier of the fragile X syndrome.''
The patient had hypothyroidism, being treated with levothyroxine. She also had a magnetic resonance imaging performed at an outside institution that identified confluent white matter changes surrounding the ventricles and extending outward to the subcortical regions, but sparing the U-fibers. The lesions showed no contrast enhancement. An electroencephalogram showed generalized slowing, more severe in the right than left hemisphere with triphasic waves frontally.
Physical and Neurologic Examination
Seven years before her death, her general physical examination in our clinic was unremarkable. Neurologic examination revealed ocular saccadic pursuit, a positive Myerson sign, and a mask like face. She had a resting tremor of her right hand and cogwheel rigidity with some superimposed paratonia (gegenhalten) of her limbs. Her finger movements on the right were normal, but slightly slowed and hypometric on the left. With finger to nose testing there was no action-intention tremor, dysmetria, or ataxia. Her gait was slightly slow with a decreased arm swing but no ataxia. She was able to walk on her toes and heels and she had a negative Romberg test but was a little unstable with the ''push'' test. She also had motor impersistence and grasp reflexes. Her proprioception and vibration were normal in her feet and graphesthesia was normal.
Mental Status Testing
The patient had a profound bradyphrenia with notably long delays (2 to 3 min) in responses, especially verbally. In general, the patient demonstrated severe frontal-executive and amnesic disorders, but her language was also impaired. The result of this test can be found in the Table 1 .
Laboratory Tests
All of the following diagnostic tests were normal: thyroid stimulating hormone, thyroxine 4, thyroxine 3, B12, folate, serologic test for syphilis, ceruloplasmin, sedimentation rate, human immunodeficiency virus, herpes simplex virus-polymerase chain reaction, lupus anticoagulant, and polypurine tract. Perinuclear and circulating antineutrophil cytoplasmic antibodies were negative and the serum angiotensin converting enzyme level was within normal limits. Serum levels of arylsulfatase-A, galactosylceramide b-galactosidase, microsomal antibodies, antithroglobin, and long-chain fatty acids were within normal limits. The patient also had a lumbar puncture, which had 17 red blood cells, but no white blood cells, protein 59 mg/dL, and glucose of 64 mg/dL. Oligoclonal bands, myelin basic protein, polymerase chain reactions for JC virus and HSV, and 14-3-3 were also normal. A skin biopsy to exclude the possibility of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy was negative.
Neuropathology
The patient died about 7 years after our clinic evaluation. On post-mortem examination the brain weighed 1040 g and showed mild sulcal widening that was most prominent in the frontal and temporal perisylvian regions. There was diffuse, symmetrical, ventriculomegaly with reduction in white matter volume, particularly of the corpus callosum and subcortical white matter (Fig. 1A) . The centrum semiovale was relatively uninvolved. The subcortical white matter of the frontal and parietal regions (temporal and occipital regions less affected) were gray and translucent ( Fig. 1A) with sparing of the subcortical white matter. There was mild reduction in the volumes of the hippocampus and cingulate gyri. The cerebellar peduncles were grossly unremarkable. The substantia nigra was well pigmented and no gross lesions were observed in the brainstem.
Histologic study revealed pallor of the subcortical white matter on hematoxylin and eosin and Luxol fast blue-periodic acid-Schiff stains with relative sparing of U-fibers (axons located immediately beneath the sixth cortical layer) (Figs. 1B, C) . There was also reactive white matter gliosis in areas of myelin pallor but no evidence of inflammation or macrophage accumulation. A particularly striking finding was the presence of many protoplasmic astrocytes, some with Alzheimer type 2-like appearance, that contained prominent eosinophilic intranuclear inclusions ( Fig. 2A) . Such structures were also present within the nuclei of many cortical neurons including those of the hippocampus (Fig. 2B) . Astrocytic intranuclear inclusions were immunoreactive for ubiquitin and were identified in virtually every section of cerebral cortex (Figs. 2C, D) . Neuronal intranuclear inclusions, which were also strongly ubiquitin reactive and were most numerous in areas of gross cerebral atrophy as well as in the hippocampal formation and adjacent structures (Fig. 2E) . The basal ganglia and thalamus also contained many astrocytes and neurons with ubiquitin-reactive intranuclear inclusions. In contrast, neurons of the substantia nigra showed little neurodegenerative change, although a few collections of pigment-containing macrophages were seen and astrocytes with intranuclear inclusions were also present. Mesencephalic neurons of the tegmentum contained intranuclear ubiquitin-immunoreactive inclusions as did a few medullary tegmental neurons. Intranuclear inclusions were also occasionally seen in fibrous astrocytes of the white matter and cerebellar Bergmann glia. In general, neuronal intranuclear inclusions were uniformly positive for ubiquitin, whereas glial intranuclear inclusions varied in their immunoreactivity from strongly reactive to occasionally nonreactive. Intranuclear inclusions were nonreactive for tau, b-amyloid, and a-synuclein by immunohistochemistry.
Multiple sections of cerebral cortex from frontal lobe (including cingulate gyrus, superior frontal, and orbital frontal gyri) to temporal regions (including superior temporal gyrus, entorhinal cortex, subiculum, and hippocampus proper) revealed generally mild amounts of atrophy with apparent neuronal loss and gliosis. The presence of scattered neurons that contained tau-positive neurofibrillary tangles and neuropil threads in frontal and temporal cortices was confirmed by immunohistochemistry. Beta-amyloid-immunoreactive neuritic plaques of the diffuse type were identified, although only a few plaques with amyloid cores were seen. Although the cortical distribution of these Alzheimer-like neurodegenerative changes occurred in fronto-temporal association areas, the density of amyloid plaques and neurofibrillary tangles was not sufficient for a diagnosis of Alzheimer disease (AD). 6 Many small arterial blood vessels of the subarachnoid space and cerebral cortex showed extensive b-amyloid immunoreactivity consistent with cerebral amyloid angiopathy. No Lewy body pathology was identified and no a-synuclein immunoreactivity was identified in any section tested.
DISCUSSION
In the clinic, the co-occurrence of PD is frequently observed. Although this patient's impaired memory, naming, and executive functions could have been induced by a Parkinson-dementia complex caused by either Lewy bodies or a combination of PD with AD, from the clinical perspective these combinations would seem to be unlikely, because she had a very unusual speech language disorder marked by profound nonfluency which is not typical of either of the forms of dementia. Patients with frontotemporal lobar degeneration and primary progressive nonfluent aphasia might also demonstrate features of parkinsonism. Some of these patients go on to develop signs of corticobasal degeneration and some patients have been found to have a LRRK2 mutation. 7 In addition, although patients with AD often show more frequent and more severe leukoaraiosis than do age matched controls, this patient's white matter disease exceed the degree of leukoaraiosis most commonly seen with AD. With this extensive white matter disease, this patient underwent and extensive evaluation to learn if she had a form leukodystrophy such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy or metachromatic, but theses evaluations were negative.
About 20% of people with FXTAS can develop a dementia, but until a recent case report of a woman with dementia 8 these have all been men. The woman described B C A in this report, like the men with FXTAS, had ataxia and an intention tremor with evidence of white matter changes in the cerebral peduncle. Our patient, however, was not ataxic, did not have an intention tremor or a peripheral neuropathy. Thus, our patient's clinical profile was different than that associated with FXTAS and she had a syndrome that has not been previously reported and that we call fragile X dementia parkinsonism syndrome.
At the time this patient was seen in our clinic, genetic testing was not obtained as she did not show signs of FXTAS. When the underlying pathology was discovered by post-mortem examination, the material was sent to an outside laboratory for testing, but due to excessive formalin fixation, definitive results were not obtained. Thus, it is not certain if she was a ''premutation carrier'' (55 to 200 repeats) or had a full mutation, but because she probably had a protective effect of the second X chromosome. This genetic defect usually impairs the normal production of the FMR protein, which is believed to be important for synaptic plasticity. Although our patient might have had this defect in plasticity, the severe disorder of her white matter probably accounted for much of her dementia.
The white matter pathology (pallor on myelin staining and reactive gliosis) in this patient was primarily subcortical, leaving the centrum semiovale relatively spared. In addition, she had striking intranuclear ubiquitinimmunoreactive inclusions of protoplasmic astrocytes and neurons (especially neurons of the hippocampal pyramidal cell layer). Less severe pathology was found in the cerebellum, but unlike patients with FXTAS, the peduncles were not involved, although some intranuclear inclusions were found in the Bergmann glia. These findings are quite similar to those described in FXTAS 9 where the genetic mutation is believed to increase mRNA copy number, leading to increased binding of other cellular proteins. This sequestration process may lead to abnormal protein processing and proteosomal degradation via ubiquitin pathways with ultimate nuclear accumulations (inclusions). 10 Although this disorder usually affects males, females may be affected due to X-chromosome inactivation. 11 In addition to neuropathologic changes related to FXTAS, in our patient there was some mild Alzheimer-like neurofibrillary pathology and some amyloid angiopathy. The combination of FXTAS and Alzheimer-like brain pathology has also been described. 12 To our knowledge this patient's dementia-Parkinson syndrome has not been previously reported and this disorder might be more common than expected. Thus, patients who develop a PD should have magnetic resonance imaging to see if they have extensive white matter disease and learning if they are carriers of the Fragile X gene.
